A case of juvenile amyopathic dermatomyositis with anti‐transcription intermediary factor 1‐α antibody showing negative anti‐TIF1‐γ ELISA results: Comment on "Case of pembrolizumab‐induced dermatomyositis with anti‐transcription intermediary factor 1‐γ antibody". Issue 1 (29th September 2022)